Skip to main content
. 2022 Aug 26;22:921. doi: 10.1186/s12885-022-10009-4

Table 2.

Univariable and multivariable analysis of parameters for progression-free survival

Parameters Univariable analysis Multivariable analysis
HR 95% CI P value HR 95% CI P value
Age ≥ 60 years 0.993 0.783—1.260 0.957
Female 0.957 0.752—1.217 0.719
BMI ≥ 24 kg/m2 0.891 0.706—1.124 0.328
ASA score 1–2 1.051 0.724—1.526 0.794
Primary site colon 1.052 0.833—1.330 0.669
Right hemicolon 1.066 0.781—1.453 0.688
R0 resectiona 0.515 0.404—0.658 < 0.001* 0.583 0.453—0.748 < 0.001*
Poorly differentiateda 1.286 0.990—1.671 0.060 0.684
T3-T4a 1.490 0.935—2.374 0.093 0.262
N1-N2a 1.749 1.332—2.295 < 0.001* 1.511 1.145—1.994 0.004*
Synchronous metastasisa 1.451 1.087—1.937 0.012* 0.143
Extrahepatic metastasesa 1.612 1.160—2.239 0.004* 1.416 1.015—1.976 0.041*
Diameter of metastases > 5 cm 1.038 0.722—1.492 0.841
Multiple metastasesa 1.997 1.571—2.539 < 0.001* 0.063
Bilobar distributiona 2.035 1.603—2.583 < 0.001* 0.115
Preoperative CEA > 50 ng/mla 1.569 1.183—2.082 0.002* 1.400 1.053—1.861 0.021*
Major liver resectiona 1.978 1.563—2.503 < 0.001* 1.615 1.266—2.060 < 0.001*
Hepatectomy only 0.869 0.678—1.113 0.267
Radio frequency ablationa 1.818 1.289—2.565 0.001* 0.153
Preoperative chemotherapya 1.481 1.170—1.874 0.001* 0.204
Postoperative chemotherapy 0.870 0.689—1.098 0.241
Comorbidity 0.960 0.760—1.213 0.731
Postoperative complicationa 1.393 1.103—1.757 0.005* 0.161
Postoperative major complication 1.120 0.827—1.517 0.463
Serious operation injury conditiona 1.616 1.279—2.042 < 0.001* 0.062
AMLRI > 3.33a 1.530 1.114—2.101 0.009* 1.462 1.059—2.019 0.021 *
AST > 14 U/L 1.697 1.133—2.542 0.010*
MLR > 0.15 1.397 0.953—2.046 0.086
Blood loss (ml) 1.521 1.157—1.999 0.003*
Operation time (min) 1.572 1.240—1.993 < 0.001*
CRS 3–5 1.608 1.272—2.032 < 0.001*

BMI body mass index, ASA American Society of Anesthesiologists T tumour staging, N lymph node staging, CEA carcinoembryonic antigen, CRS clinical risk score, AMLRI AST·MLR index, AST aspartate aminotransferase, MLR monocyte-to-lymphocyte ratio

aIncluded in multivariable analysis

*Statistically significant